Abstract
Synthetic and biological vesicular carriers have been recognized as attractive and intelligent systems for delivery of a verity of bioactive molecules. The importance of such delivery systems can be mostly due to their physicochemical properties, i.e. a lipid bilayer surrounding an aqueous core which allows encapsulation and protection of active hydrophilic molecules such as nucleic acids. Synthetic vesicles such as liposomes have been studied as gene delivery systems for decades. However, due to their fast clearance, toxicity and immunogenicity which impose restrictions on clinical applications, some other natural lipid vesicles such as exosomes have been considered as alternatives. Attractive features of nature's own ‘nano-vesicles’ such as exosomes, virosomes, bacterial ghosts and erythrocyte ghosts include efficient cellular entry, physicochemical properties and evading immune responses. Nevertheless, there are advantages and disadvantages with both synthetic and biological vesicular systems. Here, we provide an overview into different vesicle-based gene delivery systems and discuss how various modifications in their structure and formulations could improve the transfection efficiency and decrease the toxicity.
Keywords: Gene delivery, vesicular systems, liposomes, biological vesicles.
Current Pharmaceutical Design
Title:Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery
Volume: 21 Issue: 42
Author(s): Fatemeh Soltani, Hamideh Parhiz, Ahad Mokhtarzadeh and Mohammad Ramezani
Affiliation:
Keywords: Gene delivery, vesicular systems, liposomes, biological vesicles.
Abstract: Synthetic and biological vesicular carriers have been recognized as attractive and intelligent systems for delivery of a verity of bioactive molecules. The importance of such delivery systems can be mostly due to their physicochemical properties, i.e. a lipid bilayer surrounding an aqueous core which allows encapsulation and protection of active hydrophilic molecules such as nucleic acids. Synthetic vesicles such as liposomes have been studied as gene delivery systems for decades. However, due to their fast clearance, toxicity and immunogenicity which impose restrictions on clinical applications, some other natural lipid vesicles such as exosomes have been considered as alternatives. Attractive features of nature's own ‘nano-vesicles’ such as exosomes, virosomes, bacterial ghosts and erythrocyte ghosts include efficient cellular entry, physicochemical properties and evading immune responses. Nevertheless, there are advantages and disadvantages with both synthetic and biological vesicular systems. Here, we provide an overview into different vesicle-based gene delivery systems and discuss how various modifications in their structure and formulations could improve the transfection efficiency and decrease the toxicity.
Export Options
About this article
Cite this article as:
Soltani Fatemeh, Parhiz Hamideh, Mokhtarzadeh Ahad and Ramezani Mohammad, Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery, Current Pharmaceutical Design 2015; 21 (42) . https://dx.doi.org/10.2174/1381612821666151027153410
DOI https://dx.doi.org/10.2174/1381612821666151027153410 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Allosteric Enhancers of A1 Adenosine Receptors: State of the Art and New Horizons for Drug Development
Current Medicinal Chemistry The Vasoactive Role of Nitric Oxide: Physiological and Morphological Aspects
Current Pharmaceutical Biotechnology Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Cardiovascular & Hematological Disorders-Drug Targets Mild Mitochondrial Uncoupling as a Therapeutic Strategy
Current Drug Targets In vivo Optical Molecular Imaging of Cardiovascular Diseases: Long Road Ahead
Current Molecular Imaging (Discontinued) Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond
Current Medicinal Chemistry <sup>11</sup>C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications
Current Radiopharmaceuticals Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology